0001507567-23-000003.txt : 20230105
0001507567-23-000003.hdr.sgml : 20230105
20230105162133
ACCESSION NUMBER: 0001507567-23-000003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Booth Robert F.
CENTRAL INDEX KEY: 0001507567
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 23511612
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS, INC.
STREET 2: 995 EAST ARQUES AVENUE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 617-514-7149
MAIL ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
wf-form4_167295366118350.xml
FORM 4
X0306
4
2023-01-03
0
0001599298
Summit Therapeutics Inc.
SMMT
0001507567
Booth Robert F.
C/O SUMMIT THERAPEUTICS INC.
2882 SAND HILL ROAD, SUITE 106
MENLO PARK
CA
94025
1
0
0
0
Stock Option (right to buy)
5.0
2023-01-03
4
A
0
35000
A
2033-01-03
Common Stock
35000.0
35000
D
Stock Option (right to buy)
5.0
2023-01-03
4
A
0
32700
1.67
A
2033-01-03
Common Stock
32700.0
67700
D
The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date.
Not applicable.
The option was issued on January 3, 2023. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-employee director on each such vesting date.
The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $54,500.
/s/ Ankur Dhingra, as Attorney-in-Fact for Robert F. Booth
2023-01-05